Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN)
A Multicentre Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment
Sponsor: Centre Leon Berard
Listed as NCT04698785, this PHASE2 trial focuses on Bone Sarcoma and Osteosarcoma and remains actively recruiting participants. Sponsored by Centre Leon Berard, it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Oct 2024 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2022 — Sep 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Leon Berard
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Besançon, France , Bordeaux, France , Dijon, France , Lille, France , Lyon, France , Marseille, France , Montpellier, France , Nantes, France , Paris, France , Saint-Herblain, France and 4 more locations